ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,402.00
0.27%
S&P ASX All Technology
3,968.40
1.71%
Brent Oil
75.305
-0.07%
US Dollar vs AUD
1.61236
0.25%
Bitcoin
100,298.52
-1.10%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Assertio Holdings Inc (ASRT) Share Price

Assertio Holdings Inc

Assertio Holdings Inc (ASRT)

BNP Paribas Asset Management Luxembourg
0.81
0.0074
(0.92%)
Closed 04 February 8:00AM
Delayed by 15 minutes
0.824
0.014
(1.73%)
After Hours: 11:35AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.824
Bid
0.8004
Offer
0.824
Volume
265,520
0.7802 Day's Range 0.816
0.7324 52 Week Range 1.798
Market Cap
78.674M
Previous Close
0.8026
Open
0.791
Last Trade
105
@
0.824
(formt)
Last Trade Time
Financial Volume
US$ 212,045
VWAP
0.798602
Average Volume (3m)
737,536
Shares Outstanding
95,477,800
Dividend Yield
-
PE Ratio
-0.23
Earnings Per Share (EPS)
-3.48
Revenue
152.07M
Net Profit
-331.94M

About Assertio Holdings Inc

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management... Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.assertiotx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Assertio Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ASRT. The last closing price for Assertio was US$0.80. Over the last year, Assertio shares have traded in a share price range of US$ 0.7324 to US$ 1.798.

Assertio currently has 95,477,800 shares in issue. The market capitalisation of Assertio is US$76.63 million. Assertio has a price to earnings ratio (PE ratio) of -0.23.

Ask ADVFN Intelligence (AI)

ASRT Latest News

More News

Form 8-K - Current report

29 January 2025
Edgar (US Regulatory)

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

04 January 2025
GlobeNewswire Inc.

Form 8-K - Current report

18 December 2024
Edgar (US Regulatory)

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

18 December 2024
GlobeNewswire Inc.

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

14 December 2024
GlobeNewswire Inc.

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

13 December 2024
GlobeNewswire Inc.

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

06 December 2024
GlobeNewswire Inc.

Form 8-K - Current report

13 November 2024
Edgar (US Regulatory)

Assertio Reports Third Quarter 2024 Financial Results

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE...

12 November 2024
GlobeNewswire Inc.

Assertio Provides Response to Letter from Short-seller

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company...

11 November 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.006-0.7228915662650.830.83490.79012899640.81594006CS
4-0.064-7.207207207210.8880.93910.78014120770.82998899CS
12-0.1092-11.70167166740.93321.080.787375360.9052412CS
26-0.371-31.04602510461.1951.380.786503851.0151403CS
520.0394.968152866240.7851.7980.73248479341.08414826CS
156-1.656-66.77419354842.488.010.732412494563.1857612CS
260-0.226-21.52380952381.058.010.3322031611.66889951CS

ASRT - Frequently Asked Questions (FAQ)

What is the current Assertio share price?
The current share price of Assertio is US$ 0.824
How many Assertio shares are in issue?
Assertio has 95,477,800 shares in issue
What is the market cap of Assertio?
The market capitalisation of Assertio is USD 76.63M
What is the 1 year trading range for Assertio share price?
Assertio has traded in the range of US$ 0.7324 to US$ 1.798 during the past year
What is the PE ratio of Assertio?
The price to earnings ratio of Assertio is -0.23
What is the cash to sales ratio of Assertio?
The cash to sales ratio of Assertio is 0.51
What is the reporting currency for Assertio?
Assertio reports financial results in USD
What is the latest annual turnover for Assertio?
The latest annual turnover of Assertio is USD 152.07M
What is the latest annual profit for Assertio?
The latest annual profit of Assertio is USD -331.94M
What is the registered address of Assertio?
The registered address for Assertio is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Assertio website address?
The website address for Assertio is www.assertiotx.com
Which industry sector does Assertio operate in?
Assertio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IVVDInvivyd Inc
US$ 1.055
(194.94%)
448.53M
HCWBHCW Biologics Inc
US$ 0.6265
(125.20%)
344.42M
UOKAMDJM Ltd
US$ 0.2293
(76.38%)
354.09M
GHRSGH Research PLC
US$ 17.9991
(69.80%)
10.31M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 234.64
(61.82%)
392
CYNCYNGN Inc
US$ 0.1169
(-56.70%)
75.52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.1943
(-54.61%)
327.95M
VIRXViracta Therapeutics Inc
US$ 0.0741
(-51.09%)
9.37M
BOWNUBowen Acquisition Corporation
US$ 3.39
(-49.55%)
17.28k
PITAHeramba Electric PLC
US$ 0.503
(-44.11%)
1.37M
IVVDInvivyd Inc
US$ 1.055
(194.94%)
431.26M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0462
(27.98%)
400.25M
NVDANVIDIA Corporation
US$ 116.66
(-2.84%)
333.74M
UOKAMDJM Ltd
US$ 0.2293
(76.38%)
326.81M
HCWBHCW Biologics Inc
US$ 0.6265
(125.20%)
320.82M

ASRT Discussion

View Posts
dcaf7 dcaf7 4 days ago
I don't know. Possibly, they want to focus on business aspects of same day dosing in this poster presentation.
👍️ 1
ATLcitizen ATLcitizen 4 days ago
Interesting that they are presenting at a business summit, not scientific conference (which they have already done). What do they expect to gain? Is this for the insurance industry?
👍️ 1
dcaf7 dcaf7 5 days ago
Data from same day dosing trial will be presented at ACCC 51st Annual Meeting & Cancer Center Business Summit on March 5, 2025. Title: Eflapegrastim, a Long-Acting GCSF, Administered the Same Day as Chemotherapy in Patients with Early-Stage Breast Cancer: Results from a Multicenter, Open-Label, Study.
👍️ 2
dcaf7 dcaf7 2 months ago
Maxim Group analyst Naz Rahman has reiterated their bullish stance on ASRT stock, giving a Buy rating today.
Dec 16, 2024, 01:45 PM
Naz Rahman has given his Buy rating due to a combination of factors related to Assertio Therapeutics’ recent clinical study results. The same-day dosing study of Rolvedon, presented at the San Antonio Breast Cancer Symposium, demonstrated favorable outcomes for patients, including rapid recovery of neutrophil counts and a very low incidence of febrile neutropenia. This aligns well with the results from the Phase 3 trial, reinforcing the drug’s safety and efficacy profile.
Furthermore, there were no new safety concerns, and the adverse event profile remained consistent with previous trials. The potential for Rolvedon to be incorporated into the National Comprehensive Cancer Network guidelines could also boost its market penetration and sales growth. With these positive indicators, Rahman perceives significant sales potential for Rolvedon, contributing to the Buy rating for Assertio Therapeutics.
https://www.tipranks.com/news/blurbs/positive-clinical-results-and-market-potential-drive-buy-rating-for-assertio-therapeutics
👍️0
dcaf7 dcaf7 2 months ago
On Monday, H.C. Wainwright maintained its Buy rating and a price target of $4.00 for Assertio Therapeutics shares
The firm's stance follows Assertio Holdings' recent announcement of clinical trial results for ROLVEDON (eflapegrastim-xnst) injection. The trial focused on the drug's same-day dosing alongside chemotherapy in patients with early-stage breast cancer (ESBC).
The study, identified as NCT04187898, was an open-label, single-arm trial conducted at 13 U.S. sites. Participants were administered ROLVEDON 30 minutes after receiving chemotherapy for ESBC. Findings from the trial indicated a neutrophil count recovery time of 1.8 days and a febrile neutropenia rate of 2%.
The analyst from H.C. Wainwright highlighted the convenience and dosing flexibility of ROLVEDON, particularly its same-day dosing capability. This feature was seen as an incremental but potentially significant commercial differentiator.
https://www.investing.com/news/analyst-ratings/assertio-therapeutics-shares-get-buy-rating-on-clinical-trial-results-93CH-3774534
👍️0
dcaf7 dcaf7 2 months ago
End of same day dosing hype.
👍️0
ATLcitizen ATLcitizen 2 months ago
Now we have the PR.
👍️0
dcaf7 dcaf7 2 months ago
I think you know the answer.
👍️0
Grundle Grundle 2 months ago
So no chance of Rolvedon '24 (and 25) sales being more than 175m to pay out the CVR from Spectrum?
👍️0
KRISGO KRISGO 2 months ago
Here is ChatGPT comparing Rolvedon same day with Neulasta next day..
https://media.stocktwits-cdn.com/api/3/media/510403/medium.png
https://media.stocktwits-cdn.com/api/3/media/509105/medium.png
👍️0
dcaf7 dcaf7 2 months ago
If the data had been outstanding, the company would have issued a PR on Nov 25. No need to wait until Dec 13. Most importing findings are already described in the abstract. Actual presentation won't add much.
👍️ 1
KRISGO KRISGO 2 months ago
It looks like the company will be presenting these results at a conference on December 13th. The following message is from a poster named "D_S" on StockTwits.
"D_S: Nov 29, 2024 9:44 AM : $ASRT The abstract link showed back up again on the San Antonio Breast Conference website. ASRT's abstract is there. As such there is not an "embargo" on them releasing a pr. However, that pr can only discuss the abstract information, not fully discuss the research. It's part of the requirement to have research presented at this conference----they want the research discussed first there. So here is my opinion.....if same-day dosing results are only to be about the convenience of patients not having to go to a 2nd day visit, then ASRT puts out a simple pr on day of poster presentation (after market closes). If same-day dosing results are showing (as we think from analysis of abstract) that giving the infection on day of chemo reduces severe neutropenia vs next day dosing, then I think there could be chance of cc call (on top of pr) to discuss implications. CEO needs the stock price up to give him options for future large acquisition potentially, but at least to give investors confidence"
👍️0
dcaf7 dcaf7 2 months ago
The abstract is on SABCS website since Nov 25, 2024, not leaked. Data is OK, but Rolvedon won't be approved as same day injection. I don't think, it will boost sales much. Looks like market has same opinion. And ASRT doesn't even bother to issue a PR on these results.
👍️0
KRISGO KRISGO 2 months ago
I'm referring to the same-day dosing of Rovedon. The full abstract from ASRT has been leaked on San Antonio Breast Cancer Conference website, which is definitely positive news. It has the potential to boost sales and is gaining attention, but the stock doesn't seem to be moving upward. Any thoughts on why that is?
👍️0
dcaf7 dcaf7 2 months ago
Nothing really changed. Rolvedon doesn't look different from Neulasta and multiple biosimilars. Sales have remained flat over the last three quarters.
👍️0
dcaf7 dcaf7 2 months ago
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company NASDAQ: CHRS,) today announced that it has entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for the divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise for up to $558.4 million.
👍️0
KRISGO KRISGO 2 months ago
Hey guys, any idea why this stock isn't moving up? Rolvedon looks promising and definitely has long-term potential. The info seems to be out there, and the street is aware of it, but it’s not gaining any momentum. Any thoughts?
👍️0
KRISGO KRISGO 2 months ago
got it, thanks dcaf7!
👍️0
dcaf7 dcaf7 2 months ago
This trial was not design to demonstrate significant advantage. As you can read in the Conclusions, same day dosing "may be advantageous in reducing the time to ANC recovery". Just may be. This data will not result in label change, but it might be included in NCCN guidelines.
👍️0
KRISGO KRISGO 2 months ago
dcaf7, thanks for sharing this. I'm not an expert in this area, so I'm not sure if this study offers a significant advantage over existing ones. What’s your take on it?
👍️0
dcaf7 dcaf7 2 months ago
From the abstract
The primary endpoint was the time to recovery of absolute neutrophil counts (ANC) from nadir to ? 1.5×109/L in C1. Secondary endpoints included incidence of SN (ANC < 0.5×109/L) and FN (ANC < 1.0×109/L and temperature of > 38.3 oC or 2 consecutive readings ?
38.0 oC over 2 hours), duration of SN (DSN), and incidence of neutropenic complications, including use of antibiotics and/or hospitalizations.
Results: A total of 53 pts (mean [SD] age: 62.7 [11.9] years; female: 100%) from 13 sites across the US, were enrolled (White: 62.3%; Black or African American: 9.4%; others: 28.3%). Pts were relatively healthy (ECOG 0, 52.8% [n = 28] patients; ECOG 1, 47.2% [n =
25] patients). Efficacy in C1 was evaluable in 49 patients. Mean (SD) time to ANC recovery was 1.8 (1.1) days. Incidence of SN was 46.9% (n = 23) and mean (SD) DSN was 0.8 (1.0) days. Incidence of FN was 2% (n = 1). No neutropenic complications were observed during the study. Safety was assessed in all 53 patients who received at least 1 dose of eflapegrastim. Overall, 43 patients (81.1%) experienced any TEAE of musculoskeletal pain. Common musculoskeletal-related TEAEs experienced by ? 10% of patients were bone pain (52.8%; n = 28); back pain (26.4%; n = 14), arthralgia or pain in extremity (17.0%; n = 9 for each); and myalgia (13.2%; n = 7). No deaths were reported during the study.
Conclusions: These findings suggest that administration of eflapegrastim on the same day as TC chemotherapy may be advantageous in reducing the time to ANC recovery and related complications in pts with ESBC. The AEs observed in this study were consistent with those
generally observed in pts receiving TC and other GCSF products.
👍️ 1 🙏 1
KRISGO KRISGO 2 months ago
Thanks dcaf7 🙏
👍️0
dcaf7 dcaf7 2 months ago
They will get info about efficacy and safety but they won't be able to conclude whether this regimen works better or not.
👍️0
KRISGO KRISGO 2 months ago
Hello Dcaf7, based on the full abstract being released on Nov 25th, can the experts evaluate whether same-day dosing is effective and works better?
👍️0
dcaf7 dcaf7 3 months ago
Same day dosing data will be presented at SABCS meeting by Lee Schwartzberg on December 13, 2024.
Abstract title is "Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study". Full abstract release date is November 25, 2024.
👍️ 2
dcaf7 dcaf7 3 months ago
On earning call, they said that SPRIX might become an important asset due to NONPAIN act.
The NOPAIN Act expands patient and provider access to FDA-approved non-opioids in all outpatient surgical settings beginning in 2025 by providing separate Medicare reimbursement for non-opioid therapies.
👍️ 1
dcaf7 dcaf7 7 months ago
H.C. Wainwright starts Assertio at buy.
The investment bank said it believes Rolvedon could reach peak annual sales of around $140M in the early 2030s. It added that “long run positive traction” from products such as Rolvedon, Otrexup and Sympazan “ought to drive renewed interest from investors.”
The bank set its price target at $4.
👍️ 1
glenn1919 glenn1919 7 months ago
ASRT.......................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
ASRT................................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
ATLcitizen ATLcitizen 8 months ago
Heather Mason recently purchased 25K of ASRT shares.
👍️ 1
dcaf7 dcaf7 8 months ago
A meta-analysis of the effect of pegfilgrastim biosimilars and eflapegrastim on DSN was presented at ASCO. "Additionally, eflapegrastim, another long-acting granulocyte-colony stimulating factor agent, significantly reduced DSN compared to conventional pegfilgrastim (WMD, n = –0.13 days; 95% CI –0.24 to –0.03; P = .01). The researchers recommended “exploring the impact of the drug in clinical settings on costs and patient-reported outcomes could provide valuable insights into optimizing the management of chemotherapy-related neutropenia.”
https://www.centerforbiosimilars.com/view/asco-2024-posters-showcase-positive-data-on-denosumab-pegfilgrastim-biosimilars
👍️ 1
Propain Propain 8 months ago
bought some shares today. Gaurantee the stock will tumble now!
👍️0
dcaf7 dcaf7 9 months ago
Rolvedon/eflapegrastim is a new molecule. You cannot call it "novel formulation". Novel formulation of what? Neulasta? Nonsense.
👍️ 1
ATLcitizen ATLcitizen 9 months ago
dcaf7, please elaborate on what you mean?
👍️0
dcaf7 dcaf7 9 months ago
Listened to yesterday ASRT presentation. They call Rolvedon a "novel formulation" (slide 5). Looks like these guys don't know what Rolvedon really is.
👍️ 1
dcaf7 dcaf7 11 months ago
Rolvedon pediatric study is a postmarketing requirement from FDA. If it was up to Spectrum, they wouldn’t run it because of small commercial opportunity and approved Neulasta. I think completion of Phase 2 is what ASRT needs to accomplish. I doubt phase 3 will be required but they need to complete current study and to show the results to FDA that can happen 3-4 years away from now. As for Neulasta you can find that “no overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance”. As for same day dosing, I think, nobody knows what the next step looks like. Depends on data. Three years ago, JT said “If data is good, we would engage in a discussion with the FDA to path forward”. About a year ago, TR said the same, “whether that be going to chat with FDA about a regulatory path forward, whether it is publication, it is really contingent upon what we see in that data”.
👍️ 1
ATLcitizen ATLcitizen 11 months ago
A couple questions. A few days ago, a phase 2 study showed pediatric patients tolerated Rolvedon without requiring dose reduction. I could not copy link, but can find on Stocktwits ASRT from poster Avedesian. What is the significance? Does this mean Assertio may market to pediatric patients now, or phase 3 required? Also, this poster says that Neulasta and biosimilars required dose reduction for pediatric patients. Does this mean R is safer? How does this differentiate R from Neulasta and biosimilars? Next question: Hanmi recently said in interview with a Korean biopharma news that they expect R to be successful in their same day dosing trial to get a 'competitive edge'. IMO this appears to be a sign that they will continue with another study if the current study is successful. Another poster on X, claiming to be a doctor (this was copied on Stocktwits) said that they expect it to be short study due to requiring only one cycle of treatment. Any ideas of how long to complete another study, including enrollment? Should this be a quicker study? TIA!
👍️0
glenn1919 glenn1919 11 months ago
ASRT.........................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 11 months ago
ASRT 10Q due March 11
👍️0
dcaf7 dcaf7 11 months ago
I don’t have an answer about what does it mean. I can explain why they will finish it earlier. Because they reduced the number of patients from 90 to 50. Good sign is that trial is still enrolling. It means they think that a positive outcome is still possible. What is next if the data is good? In my opinion, for approval they need to conduct a larger trial. Not sure if they want it.
👍️ 1
ATLcitizen ATLcitizen 11 months ago
The same day dosing trial for R has moved forward its study completion date from june 2025 to july 2024. Thoughts? Is this a good sign and if successful, what is next?
👍️0
dcaf7 dcaf7 12 months ago
Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.
Published 2024.02.02

?? : KBR(https://www.koreabiomed.com)
👍️ 1
Monksdream Monksdream 1 year ago
ASRT new 52 week low
🌈 1 🍆 1 👎️ 1 🩳 1
dcaf7 dcaf7 1 year ago
What is interesting, Coherus said their injector is more patient friendly than what is used in Onpro. So, it looks like a competition of injectors now. Is it possible to win Neulasta market by introducing a better injector? Unexpected twist.
👍️ 1
ATLcitizen ATLcitizen 1 year ago
Good question, dcaf7!
👍️0
dcaf7 dcaf7 1 year ago
Shares of Coherus BioSciences (NASDAQ:CHRS) surged 36.4% after the FDA had approved an on-body injector version of the biosimilar – Udenyca for post-chemotherapy treatment Neulasta.
https://seekingalpha.com/news/4050413-biggest-stock-movers-today-coherus-biosciences-bit-digital
It will make more difficult for Rolvedon to compete. Why Spectrum or Assertio didn't start on-body injector program in addition to same day dosing?
👍️0
dcaf7 dcaf7 1 year ago
Hi ATLcitizen! Good to see you here. I think physicians view Ryzneuta the same way as Rolvedon. No clear differentiation from Neulasta. Assertio should work on same day dosing. As for Poziotinib, I don't know. I don't see any new trials with Pozi but I see several drug candidates in development that are less toxic. I found interesting document describing what exactly Spectrum did to be acquired. It looks like Hanmi was considering to buy Spectrum.
https://www.sec.gov/Archives/edgar/data/1808665/000110465923071264/tm2315184-6_s4a.htm
This acquisition story is described on pp71-82 step by step. Board was interested to sell the company when TR became a CEO. "Following the appointment of Thomas J. Riga as Spectrum’s President and Chief Executive Officer effective January 1, 2022, the Spectrum board of directors engaged in discussions regarding potential strategic alternatives at each of its regularly scheduled meetings and authorized Mr. Riga and the Spectrum management team to explore potential strategic alternatives".
👍️ 1
ATLcitizen ATLcitizen 1 year ago
What a shocker. I thought Pozi was dead. What do you think Hanmi is trying to do- get approval for 3rd line treatment? What about the whole dosing and side effects problem that FDA issued a CRL for--is Hanmi addressing that as far as you know? Do you know if MDA is still interested in investigating Pozi or have moved on? TIA.
👍️0
ATLcitizen ATLcitizen 1 year ago
Hi dcaf7! Found you again! What do you think of Ryzneuta?
👍️0
dcaf7 dcaf7 1 year ago
Ryzneuta was approved 3 weeks ago. Second "novel" long-acting G-CSF. Acrotech is going to market it in the US. It is same company that markets five Spectrum drugs.
https://acrotechbiopharma.com/wp-content/uploads/2023/11/Evive-and-Acrotech-Announce-FDA-Approval-of-Ryzneuta.pdf
👍️ 1

Your Recent History

NASDAQ
ASRT
Assertio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads